Conclusions TZP marks a revolution in WL and insulin treatments for overweight and obese patients, far surpassing the clinical efficacy of conventional interventions
This is non-negotiable based on current evidence
Many of those potential users are uninsured or underinsured, and others are needle-shy, which is a problem since GLP-1s are injected
-Cell GLP-1 in normal glucose regulation The accepted dogma of GLP-1 secreted from the intestine and acting on the pancreas in an endocrine manner is difficult to reconcile given the observations that GLP-1 is rapidly degraded by dipeptidylpeptidase 4 (DPP4) and very little, in fact, only approximately 10% of intestinally secreted GLP-1 reaches the circulation (39, 82, 93)
In late April, the companies jointly announced that Hims would be allowed to sell discounted Wegovy
Manufacturer savings programs Both Novo Nordisk (maker of Wegovy and Ozempic) and Eli Lilly (maker of Zepbound and Mounjaro) offer savings programs that can reduce out-of-pocket costs for eligible patients